JAK2 and leukemia: In oncogenic contexts such as reactive oxygen species (ROS)-driven signaling or JAK2 V617F-mutant leukemia, tyrosine phosphorylation at Y149 and Y334 by JAK2 enhances both the nuclear localization and substrate specificity of CARM177, indicating that aberrant kinase signaling sustains CARM1 in a constitutively active state.